Health Economists

Canadian public HTA and reimbursement review body supporting evidence appraisal for access decisions.

U.S.-based health economics research center (Tufts Medical Center) that curates the CEA Registry and supports cost-effectiveness and value-assessment research used in market-access decision-making.

Germany’s highest joint self-governing HTA decision body for coverage and evidence appraisal, including esketamine/Spravato dossiers.

Global HEOR professional society with major U.S. footprint and an evidence dissemination platform that includes psychedelic-adjacent esketamine budget-impact analyses.

U.S. value assessment organization that publishes comparative effectiveness and cost-effectiveness reports used by payers and policymakers, including assessments relevant to esketamine.

Nonprofit organizer and host of the Psychedelic Science conference series, alongside broader educational and policy programming.

UK HTA body issuing evidence and cost-effectiveness recommendations that influence medicine access.

State-level Oregon pharmacy and therapeutics decision body supporting evidence-driven formulary and utilization policy.

Australia’s HTA and reimbursement advisory body for PBS listing decisions, including esketamine (Spravato) assessment materials.

Scotland’s public HTA body issuing medicine acceptance guidance, including esketamine (Spravato) advice.

Washington State HTA program conducting evidence review that informs state coverage and utilization policy.